After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more programs in development and greater industry prioritization than ever before, ...

Antibody-drug conjugates are receiving unrivaled attention across the biopharma sector. Fueled by Enhertu’s tumor-agnostic accelerated approval, practice changing combination results from Seagen and ...

You may have noticed an officer standing just behind the President of India at official events, state visits, or ceremonial functions. That officer holds a very important role as an Aide-de-Camp (ADC) ...

Nigeria's two main opposition leaders have joined a new political party to challenge President BolaTinubu and his ruling party in the next election. Atiku Abubakar and Peter Obi have chosen the ...

Former Vice President Atiku Abubakar, 2023 Labour Party presidential candidate Peter Obi, former Senate President David Mark and other coalition leaders have officially adopted the African Democratic ...

In a significant shift in Nigeria’s political landscape, the Atiku Abubakar-led opposition coalition has formally adopted the African Democratic Congress (ADC) as its platform to challenge President ...

While the race is on to develop antibody-drug conjugate (ADC) cancer treatments, so too is the competition to manufacture them. Hoping to gain an edge in the rapidly growing market are MilliporeSigma ...

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal ...

ADC Therapeutics has stopped development of lead solid tumor candidate ADCT-601. The biotech axed the AXL-directed antibody-drug conjugate (ADC) after failing to show a favorable benefit-risk profile ...

Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study. Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve ...